BRIEF: GenFleet shares double in heavily oversubscribed IPO
Shares of biopharmaceutical firm GenFleet Therapeutics (Shanghai) Inc. (2595.HK) opened up 116% in their Hong Kong trading debut on Friday, and held on to the gains to close up more…
RemeGen’s $4.2 billion licensing deal falls flat with investors
The biopharma firm had fanned excitement over a rights deal for its autoimmune drug but the eventual terms, with just a small portion of upfront cash, left the market disappointed…
Dispute over Covid vaccines casts doubt on Clover Bio recovery
The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
BeiGene heads for profit milestone after hemorrhaging cash
With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…
Recent Articles
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK
688331.SHG
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK
ONC.US
688235.SHG
RELATED ARTICLES
-
BRIEF: Dahon Tech rallies in hugely oversubscribed Hong Kong IPO
2543.HK
- Intsig scans global financial markets for cash with Hong Kong IPO
-
Undervalued CICC banks on Hong Kong IPO pickup
3908.HK 601995.SHG
-
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
1276.HK 600276.SHG
- Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
-
BRIEF: Fortior shares jump in Hong Kong trading debut
1304.HK 688279.SHG
